

# ● Investor Corporate Presentation



**TSXV : LSL**

**“Fast-Growth Specialty Pharma Company”**

**February 2026**



# Disclaimer

## Confidentiality

This document is confidential and is being provided to you solely for your information and may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. This document is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum or an advertisement for, or public offering of, securities of LSL Pharma Group Inc. ("LSL Pharma" or the "Corporation"). Prospective investors should not assume that this document is complete and should conduct their own analysis and investigation of the Corporation and consult with their own financial, legal, tax and other business advisors before investing in the Corporation. By accepting and reviewing this document, you acknowledge and agree to (i) maintain its confidentiality, (ii) protect such information using at least a reasonable standard of care, and (iii) use the information solely to evaluate a potential investment in the Corporation. The information herein was prepared or obtained by the Corporation. Nothing contained herein constitutes a promise or representation as to the Corporation's future performance.

## No Offer or Solicitation

This document does not constitute an offer or solicitation to buy or sell any securities in any jurisdiction where such offer or sale would be unlawful prior to registration or qualification under applicable securities laws. Any securities to be offered have not been registered under the Securities Act (Québec) or any applicable state or foreign securities laws. Any securities to be offered in any transaction contemplated hereby have not been approved or disapproved by the United States Securities and Exchange Commission, any state securities commission or other United States or foreign regulatory authority, and will be offered and sold solely a private placement basis under Regulation D, Rule 144A or other available U.S. registration exemptions. To the extent securities are sold outside of Canada and the United States, such securities will only be sold in accordance with all the applicable laws in each case; provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction and the Corporation does not thereafter become subject to continuous disclosure obligations in such jurisdictions. This document does not constitute, or form a part of, an offer to sell or the solicitation of an offer to buy in any state or other jurisdiction to any person to whom it is unlawful to make such offer or solicitation.

## Forward Looking Information

This presentation may contain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations, estimates and intentions. The words "may", "will", "could", "should", "would", "suspect", "outlook", "believe", "plan", "anticipate", "estimate", "expect", "intend", "forecast", "objective" and "continue" (or the negative thereof) and words and expressions of similar import, are intended to identify forward-looking statements.

Forward-looking statements in this document may include, but are not limited to statements with respect to the following: the future operating or financial performance of LSL Pharma or any of its affiliates or subsidiaries; impact of the acquisition of Juno on the Corporation's financial results and operations; expectations around the Corporation's Eye-Care division and Contract Development and Manufacturing ("CMO") division, including timing, growth and production expectations; cash flow expectations and impact on the Corporation's financial results, operations and growth opportunities; expectations relating to the Corporation's growth, scalability and shareholder value creation; capital cost and expansion opportunities for the Eye-Care division and the CMO division; annual scale potential and prospective acquisition targets; operating statistics, average gross revenue, average operating margin, average production as a result of the Acquisition; the anticipated receipt of all required regulatory and third-party approvals for the Acquisition and operation of the business segment acquired as a result of the Acquisition; the expected success of the Corporation's current and future operations; the future price of the products offered by the Corporation; and any other information as to the future plans and outlook the Corporation.

Forward-looking statements are necessarily based on estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements are based on what the Corporation's management considers to be reasonable assumptions, beliefs, expectations and opinions based on the information currently available to it, as of the date such statements are made. Forward-looking statements involve known and unknown risks, uncertainties and other factors, many of which are beyond the Corporation's ability to control or predict, that may cause the actual results, performance or achievements of the Corporation to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others: inability to complete the Acquisition; general business, economic, competitive, political and social uncertainties; risks inherent in developing and commercializing healthcare products; the actual results of current production, development and sales activities; changes in labour costs or other costs of production, including risks arising from the current inflationary environment and the impact on operating costs

## Disclaimer (cont'd)

and other financial metrics; fluctuations in currency exchange rates; uncertainties inherent with conducting business in foreign jurisdictions; the government regulation of healthcare related operations; delays in obtaining governmental approvals for the completion of development activities; the availability of financing for the Corporation's development of its projects and other initiatives on reasonable terms; the success of securing or maintaining licenses, permits and authorizations; potential intellectual property disputes or claims; as well as those risk factors discussed in other documents filed by the Corporation with applicable Canadian securities regulatory authorities and available under the Corporation's profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca). This list is not exhaustive of the factors that may affect any of the Corporation's forward-looking statements.

With respect to forward-looking statements contained in this presentation, the Corporation has made assumptions regarding, among other things: the timing of obtaining regulatory and third party approvals, as well as the completion of the Acquisition and related financings; the ability of the Corporation to achieve anticipated benefits from the Acquisition; the accuracy of the price assumptions on which the statements are based; the accuracy of certain data relied upon in this presentation, such data not having been verified by a third-party; costs and timing of the development of current and future products and capital expenditures related thereto; planned future acquisitions; the adequacy of financial resources; that the Corporation will be able to obtain skilled labour and other industry services at reasonable rates; that the timing and amount of capital expenditures and the benefits therefrom will be consistent with expectations; that the conditions in general economic and financial markets will not vary materially; that the Corporation will be able to access capital, including debt, on acceptable terms; that government regulations and laws will not change materially; and that future operating costs will be consistent with the Corporation's expectations.

Forward-looking statements speak only as of the date of such information, as the case may be and may be superseded by subsequent events. LSL Pharma Group Inc. does not intend and does not assume any obligation, to update these forward-looking statements whether as a result of information, future events or otherwise.

### **Future-Oriented Financial Information and Non-IFRS Measures**

This presentation refers to future-oriented financial information, including information regarding EBITDA, adjusted EBITDA, EBITDA margin, adjusted EBITDA margin and adjusted gross margin, which are non IFRS financial measures. These measures are not recognized measures under IFRS and do not have a standardized meanings prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Corporation's results of operations from management's perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of the Corporation's financial information reported under IFRS. Such information are subject to the same assumptions, risk factors, limitations and qualifications as set forth in the above paragraphs. Please refer to "Non-IFRS financial measures" and "Reconciliation of Adjusted EBITDA" sections in the Management's Discussion and Analysis for the years ended December 31, 2024 and 2023 and for the quarters and year-to-date ended September 30, 2025 and 2024. Future-oriented financial information contained in this presentation was made as of the date hereof and was provided for the purpose of describing the anticipated effects of the Acquisition on the Corporation's business operations. LSL Pharma's actual results, performance or achievement could differ materially from those expressed in, or implied by, such future-oriented financial information. The Corporation disclaims any intention or obligation to update or revise any future-oriented financial information contained in this presentation, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the future-oriented financial information contained herein should not be used for purposes other than for which it is disclosed herein.

### **Purchaser's Right of Action for Damages and Right of Rescission**

Securities legislation in certain of the Canadian provinces provides purchasers of securities pursuant to an offering memorandum (such as this presentation) with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum and any amendment to it contains a "misrepresentation". Where used herein, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation.

Readers should refer to the applicable provisions of the securities laws of their respective province of residence for the particulars of these rights or consult with a legal advisor.

# LSL Pharma Group Business Segments

We are a rapidly growing and diversifying, integrated specialty healthcare products company headquartered in Boucherville, Quebec, Canada

## Eye-Care

Develop, manufacture and commercialize HIGH Margin Sterile Ophthalmic Ointments

- Targeting Canada, US and foreign markets

Commercializing a growing portfolio of Eye-Drops

- Exclusive and semi-exclusive rights under license for the Canadian market



## Private Label OTC

Commercialize pharmaceutical products with a focus on private label, over-the-counter (OTC) products

- Well established across all major Canadian retail pharmacies
- +40 OTC products across various indications



## Contract Development & Manufacturing ("CMO")

Contract development and manufacturing for the Canadian market

- Pharmaceuticals, natural health products, consumer health and cosmetics
- Solid, semi-solid and liquid formats
- 4 manufacturing sites





## Value Creation & Growth Strategy

### Eye-Care

Leveraging our UNIQUE manufacturing capabilities to develop High Margin “first-to-market” Generic products

FDA certification and 10X capacity expansion to dramatically impact production and revenues

- 6 new ointments under development (>80% gross margins)

Active Eye-drop in-licensing activities to help boost revenues

- Building a 30+ eye-drops product portfolio (~ 60% gross margin)

### Private Label - OTC

Leveraging our Supplier and Client network to significant expand our product portfolio

Leverage CMO Division capabilities to expand product portfolio and margins

Introduce profitable and differentiated product to the Canadian market

- Targeting up to 10 new OTC products launches in 2026 including OTC Eye-drops
- Additional growth with new prescription products

### CMO

Strategic and Organic Growth

3 acquisitions over last 2 yrs provide scale, expansion of client base and help drive synergies

\$50M manufacturing Capacity vs ~\$30M LTM revenues provide significant growth opportunity with nominal investments

- **Targeting 50% growth over the next 3 years, excluding any potential future M&A**

## LSL Financial Highlights

### Q3 2025 – YTD (9 months) Key Highlights


C\$21.4M	73%
Revenues	YoY Growth
C\$3.1M	90%
Adj. EBITDA	YoY Growth

*300%+ revenue growth over the last 2 years*

*4 acquisitions completed over last 2 years*

*Organic and M&A driven growth to continue*

### Historical Revenue Growth and EBITDA



### 2025 YTD (Sept 30) vs. Prior Periods



## Q3 Recap and YTD 2025 Highlights

We announced another record quarter for Q3 2025 with multiple key milestones and events

- 1 Strong revenue growth - Q3 2025 Revenues were up 89% over Q3 2024  
Growth reflects the impact of our Dermolab and Virage Santé acquisitions and ongoing organic growth
- 2 Secured Health Canada approval for our first 6 eye-drops to be launched in 2026 (glaucoma and allergy)
- 3 Successful acquisition of Laboratoire Du-Var adding C\$15.0M of revenue capacity and Juno OTC FY 2026 revenue forecast of \$25M
- 4 Continue to Strengthen our Balance Sheet: Completed C\$2.3M private placement and added C\$17.5M in new debt facilities at lower cost of capital. Redeemed C\$3.3M publicly listed convertible debentures and C\$5.0M high-yield private debt. 48 months Convertible debenture of C\$12M completed in December 2025
- 5 New Board Appointments: Appointment of Mr. Louis Laflamme, as independent Chairman of the Board and Mr. Noureddine Mokaddem as a new independent board member
- 6 Filed all remaining requirements to meet US-FDA requirements for our Steri-Med manufacturing site

## LSL Pharma Group History

Significant organic growth & strategic acquisitions over the last 10 years

**2014**

Acquisition of LSL Laboratory by CEO Francois Roberge

**2016**

LSL revenues soared by three times in less than 2 years

**2018**

Acquisition of Steri-Med Pharma in July

**2020**

LSL goes public on TSXV through RTO in February

*Total Revenues*

\$0.8M

\$2.5M

\$4.0M

\$7.3M

**2024**

Acquisition of Virage Santé & Dermolab Pharma

**2023**

LSL goes public on TSXV through RTO in February

\$10M

**2025**

Acquisition of Du-Var & Juno OTC

\$17.7M

**2026**

Forecast  
Revenue Guidance

~\$65M - \$70M

\$30M  
(estimated)

~35%  
5-year  
Rev. CAGR  
(2020-25)

Proven track record of opportunistically acquiring and transforming CMO businesses into high-performing, growth-focused platforms

## Proven and Experienced Team



### François Roberge – President & CEO

CPA with 30+ years of experience in finance and M&A in pharmaceutical and other businesses. Previously EVP & CFO at Jamp Pharma for 8 years. Experienced leader with expertise in manufacturing and marketing of pharmaceutical products.



### Luc Mainville – EVP, CFO

30+ years of experience in Capital Markets, primarily in the Life Science sector. Raised >\$500M, involved in 5 IPO/RTO. Previously SVP CFO Valeo Pharma, Interim CEO Acerus Pharma, CEO Neopharm Labs, CEO LAB Research. Ex-Partner/SVP KPMG Corporate Finance. Joined LSL Pharma Group in December 2023.



### Guy Paul Allard, VP Legal Affairs

Lawyer specializing in corporate and securities law for over 25 years. Has practiced in national and international law firms and previously held similar management positions in the pharmaceutical industry. Joined LSL Pharma Group in November 2024.



### Golnaz Kalantar – VP PMO – New product development

20+ years of experience in the pharmaceutical industry. Worked in project management and new product development and launch for various large pharmaceutical companies. Joined LSL Pharma Group in January 2025.



### Michael Ash – Chief Commercial Officer

25+ years of experience as pharmaceutical executive, building and scaling OTC and branded healthcare businesses in regulated markets. He leads portfolio strategy, commercialization, and growth initiatives in Canada and helped build national sales infrastructures and successfully launch multiple healthcare products.



### Sylvie Laplante – VP Quality & Compliance

25+ years of experience in the pharmaceutical and food industry, mainly in development and commercial production. Expertise in quality and cGMP compliance, GMP manufacturing, implementation or improvement of quality and compliance systems, compliance audits and regulatory inspections (FDA, WHO, EMEA, Health Canada). Joined LSL Pharma Group in January 2023.

## Proven and Experienced Team (cont'd)



**Francis Chenard – Senior VP and COO,  
LSL Laboratory**

25+ years of experience in business development and research and development in the pharmaceutical, natural health products and food sectors. Previously – 28 years with Pharmalab. Joined LSL Laboratory in January 2022.



**Sofiane Attal – Plant & Operations Director,  
Steri-Med Pharma**

15 years of experience in production management in the pharmaceutical industry. He previously worked for Biopharm and the multinational GlaxoSmithKline, holding positions as production manager, continuous improvement and corporate culture leader



**Pierre Fortin – General Director  
Dermolab Pharma**

40+ years of experience in pharmaceutical production management and business development, as well as recognized leadership in mobilizing teams and fostering innovation.



**Randy Hurst – VP Sales & Marketing,  
Juno OTC**

30+ years experience in the OTC Pharmaceutical business, starting with National Brands and moving to the Private Label side. An experienced, well regarded professional partnering with Canadian retailers and CMO's suppliers across the US, Europe & India. Joined LSL Pharma Group in January 2026.



# Board of Directors

## **Louis Laflamme**

Chairman

Mr. Laflamme is a member of the CPA Order and holds a BBA from Laval University. He is President and CEO of Antégrade Medical Inc., Previously, he was President, CEO and Director of OpSens Inc. from 2013 to 2024. He currently serves on the boards of directors of MY01 Inc., Icentia and EMKA SCIREQ Inc.

## **François Roberge**

President & CEO

## **Noureddine Mokaddem**

Director

Engineer, with 42 years of professional experience. Founder, President & CEO and Chairman of the Board of Directors of Aya Gold & Silver (AYA: TSX) from 2010 to 2020. Also Board member of Abcourt Mines (ABI: TSX-V) since 2024.

## **Mario Paradis**

Director

Currently Interim CFO of EXFO Inc. Mr. Paradis was Vice President and Chief Financial Officer of Neptune Wellness Solutions from 2015 to 2020. Prior to 2015, he was Vice President and Chief Financial Officer at Atrium Innovations.

## **Frank J. DellaFera**

Director

Founder, President and CEO of Fera Pharmaceuticals, a U.S. based specialty pharmaceutical company focused in eyecare. Previously CEO and President of Sandoz U.S., one of the world's largest and most successful generic pharmaceutical companies.

**Expecting 2 new directors to be appointed in 2026**



# Eye-Care Division

The logo for Steri-Med Pharma. It features a circular white graphic with a stylized 'S' icon composed of blue and green dots. To the right of the graphic, the words 'Steri-Med' are written in a blue sans-serif font, with 'Pharma' in a smaller, green sans-serif font below it.



## Current Product Portfolio



**STERISPORIN**  
Ophthalmic ointment  
(3.5 g)

*Sterile antibacterial ophthalmic ointment for the treatment of certain types of external eye infections such as bacterial conjunctivitis*



*Sterile antibacterial ophthalmic medication for the treatment of bacterial eye infections*



**ERYTHROMYCIN**  
Ophthalmic ointment  
(3.5 g) - Retail  
(50 x 1 g) - Hospital

## Building Our Eye-Care Product Portfolio



- 1
- 2
- 3
- 4
- 5

### US-FDA certification obtained in Q1-26

Acquiring sterile ophthalmic eye-drops through in-licensing agreements with international partners

Internal development of a range of sterile ophthalmic ointments (Rx, OTC and Vet. markets)

Commercializing products in Canada (Direct) and in the U.S. and internationally (through Partners)

New equipment to increase ointment manufacturing capacity 10X in H2-26

### New Product launches starting in 2026 expected to transform our P&L

- ➔ Eye-drops expected to contribute revenues and margins starting Mid-2026
- ➔ New Ointment products to add significant revenues and margins (80%+) starting FY-27




## Steri-Med – Increasing Capacity

	Today	2027
Manufacturing Lines	1	2
R&D Line	None	Yes
Unit Production Capacity	600K	10M+
Health Canada Certification	Yes	Yes
<u>FDA Approval for U.S. Sales</u>	<u>NO</u>	<u>YES</u>
Commercial Products	2	8
Total Adressable Market (TAM)	~C\$100M	~C\$1.5B



**Steri-Med**  
Pharma

**GROUPE**  
**LSL**  
PHARMA GROUP  
TSXV: LSL



New C\$2M production line installed  
Commissioning planned for H1-27



## Steri-Med – Internal R&D Development

### Ointments

Estimated Status / Timelines for Completion							
Products / Projects	Indication	Type	Market	Development / R&D	Regulatory / Filing	Approval	Market
Avaclyr – FERA Pharma	Herpetic Keratitis	(CMO) Ointment - Rx	Canada / U.S.			H1-2026	
SMM-0810	Corneal Edema	Ointment - OTC	Canada / U.S.			H2-2026	
SMS-0200	Dry Eyes	Ointment - OTC	Canada / U.S.			H1-2026	
SMA-0300	Dry Eyes	Medical Device	Canada / U.S.			H2-2026	
SMT-0400	Eye Infection	Ointment - Rx	Cda / U.S. / Int'l			H2-2026	
SMT-0450	Eye Infection & Inflammation	Ointment - Rx	Cda / U.S. / Int'l			H2-2026	

- Leveraging our manufacturing and development expertise to develop and launch first-to-market generic ophthalmic ointment portfolio for Canada, U.S. and international markets
- No currently marketed generic products in Canada & U.S.
- Total market size of more than C\$200M in Canada & U.S.



# Steri-Med – In-licensing Eye-Drops

Products	Indication	Type	Market	Estimated Status / Timelines for Completion					In-Licensing Fees & HC Filling	PO - \$	Canadian Market	Targeted Annual Sales - 12 - 18 months	Gross Margin - %
				Agreement Signed	Due Diligence	Filling	Approval	Market					
Latanoprost	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H2-2026	\$ -	\$88K	\$22M	\$1.2M	64%	
Latanoprost + Timolol	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H2-2026	\$ -	\$102K	\$10M	\$1.0M	70%	
Dorzolamide	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H1-2026	\$ -	\$116K	\$2.3M	\$0.5M	45%	
Dorzolamide + Timolol	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H1-2026	\$ -	\$90K	\$23M	\$1.1M	71%	
Brimonidine 5mL 0.2%	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H1-2026	\$ -	\$30K	\$1.1M	\$0.4M	46%	
Brimonidine 10 mL 0.2%	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada			H2-2025	H1-2026	\$ -	\$30K	\$1.0M	\$0.3M	61%	
Olopatadine	Allergic Conjunctivitis (Pink Eye)	Eye-drop - Rx	Canada			H2-2025	H1-2026	\$ -	\$270K	\$6.7M	\$1.5M	66%	
SHS-B505	Seasonal Allergic Conjunctivitis	Eye-drop – Rx	Canada		H2-2026			H2-2027					
SHS-B510	Eye Inflammation & Pain	Eye-drop – Rx	Canada		H2-2026			H2-2027					
SHS-B515	Eye Inflammation & Pain	Gel – Rx	Canada		H2-2026			H2-2027					
SHS-B600	Glaucoma, Ocular Hypertension & Hypotrichosis	Eye-drop – Rx	Canada			H2-2026		H2-2026	\$85K	\$80K	\$54M	\$3.5M	71%
SHO-B701	Allergic Conjunctivitis (Pink Eye)	Eye-drop – Rx	Canada			H1-2026		H2-2026	\$50K	\$70K	\$6.7M	\$1.5M	84%
SHO-B702	Allergic Conjunctivitis (Pink Eye)	Eye-drop – Rx	Canada			H1-2026		H2-2026	\$50K	\$304K	\$14.9M	\$1.8M	82%
SHC-B800	Acute Otitis Externa & Acute Otitis Media	Eye-drop – Rx	Canada		H2-2026			H1-2027					
SHL-B905	Glaucoma & Ocular Hypertension	Eye-drop – Rx	Canada		H2-2026			H1-2027					
SHT-B910	Glaucoma & Ocular Hypertension	Eye-drop - Rx	Canada		H2-2026			H1-2027					

Note: First 7 products are approved and have been signed with Generic Medical Partners. Other pipeline products are in-licensed from Sentiss Pharma.

- Total Canadian domestic market size estimated at more than C\$160M
- The goal is to build an eye-drops portfolio (Rx & OTC) of 35 to 50 products within 3 years



# Private label OTC

The logo for Juno OTC. It consists of the word "juno." in a blue, lowercase, sans-serif font, with a small trademark symbol (TM) to the right, and "OTC" in a smaller, blue, lowercase, sans-serif font directly below it.



## Juno OTC Products and Banners

*Expanding our offerings and national reach to effectively serve Ontario and Western Canada while adding a profitable, diversified revenue stream*


### 40+ OTC Products Across Various Categories

Denture	Antacid	Hydralax	Fibre Laxative	Allergy
Diarrhea Relief	Cold & Flu	Nicotine Gum	Acetaminophen	Bismuth
Cold Cough Powder	Sleep Aid	Nasal Spray	Ibuprofen	Probiotic
OTC Eye Drops	Epsom Salts	Feminine Wash	Personal Lubricant	Acetaminophen & Ibuprofen Liquids (Pediatric)

### Banner Presence Across Canada



### Increased Presence in Ontario and Western Canada



**~77%**  
non-Quebec  
sales mix



# CMO Division



## CMO Site Map and Capabilities



Québec City  
Montréal  
*LSL Corporate HQ*



Pharmaceuticals and Natural Health Products Focus  
Private Label: Tablets, Capsules, Sachets, Powders  
Development Services  
*La Pocatiere, QC (22K sq. ft.)*

Natural Health Products Focus  
Private Label: Sachets, Tablets, Capsules, Powders  
Development Services  
*Levis, QC (8K sq. ft.)*

Personal Health, Consumer, Cosmetics, Veterinary  
Private Label: Semi-Solids and Liquids  
*Boucherville, QC (31K sq. ft.)*

Personal Health, Consumer and Cosmetics  
Private Label: Semi-Solids and Liquids  
*St-Julie, QC (51K sq. ft.)*



**Steri-Med**  
Pharma

Sterile ophthalmic ointments manufacturing with future CMO capabilities

## Current Capitalization and Ownership

### Current Capitalization

*In C\$ 000s, except share price*


#### Current Capitalization (TSXV:LSL)

Price - as at Jan 30, 2026	0,55 \$
Basic Shares O/S	126 730
Basic Market Cap	69 701 \$
Net debt	29 703 \$
Enterprise Value	99 404 \$

#### Equity Capital Structure

Basic Shares O/S	126 730
Options (average strike \$0.58)	8 855
Unsecured convertible debt @ \$0.45	26 667
Warrants (average strike \$0.70)	41 871
<b>Fully-Diluted Shares</b>	<b>204 122</b>

### Ownership Summary (Basic)





## LSL Upcoming Milestones in Next 12-18 months



### Eye-Care Segment

- File 3 first-to-market generics in FY-26 for Canada and U.S.
- Commercial launch of 6 eye-drops in Q2-Q3 2026
- In-license 10 additional eye-drop products
- Commissioning of new state-of-the-art ointment manufacturing line

### Private label OTC Segment

- Fully integrate December 2025 Juno OTC acquisition
- Launch up to 10 new OTC products and new prescription products


### CMO Segment

- Fully integrate recently acquired 4<sup>th</sup> site (Laboratoire Du-Var)

### Financial & Corporate

- Profitability by year-end

## Investment Highlights



LSL is turning the corner with financial performance and strong growth supported by market dynamics allowing the Eye-Care and CMO segments to create value alongside a new segment strategy with Juno OTC



# Thank you!

**François Roberge, President & CEO**

[froberge@groupelslpharma.com](mailto:froberge@groupelslpharma.com)  
514.629.3312

**Luc Mainville, EVP & CFO**

[lmainville@groupelslpharma.com](mailto:lmainville@groupelslpharma.com)  
438.826.1426

T

514.664.7700

A

1800-540, D'Avaugour  
Boucherville, QC  
J4B 0G6

W

[www.groupelslpharma.com](http://www.groupelslpharma.com)